Mounjaro Kwik Pen

Mounjaro (tirzepatide) is used to treat type 2 diabetes and support weight loss in eligible patients. It helps regulate blood sugar levels and reduces appetite when used alongside diet and exercise.

Mounjaro works by mimicking the hormones GLP-1 and GIP, which help control appetite, slow digestion, and increase feelings of fullness. This leads to reduced calorie intake and gradual weight loss over time.

Mounjaro is a once-weekly injection. It should be injected on the same day each week, with or without food.

The most common side effects include nausea, vomiting, diarrhoea, constipation, reduced appetite, and stomach discomfort. These are usually mild and improve over time.

Side effects are usually temporary and most commonly occur when starting treatment or increasing the dose. Symptoms often improve within a few days to a few weeks.

Mounjaro is considered safe when prescribed and monitored by a healthcare professional. Like all medicines, it can cause side effects, so regular medical supervision is important.

Mounjaro is prescribed to adults with type 2 diabetes or individuals who meet specific BMI and health criteria for weight management under UK clinical guidelines.

Mounjaro is injected under the skin (subcutaneously) in the abdomen, thigh, or upper arm. It is important to rotate injection sites each week to reduce irritation.

You should not stop Mounjaro without medical advice. Stopping treatment may lead to increased appetite and possible weight regain.

Some people may regain weight after stopping treatment if lifestyle changes are not maintained. Diet, exercise, and healthy habits are important for long-term results.

Mounjaro usually starts at a low dose (commonly 2.5 mg once weekly) and is gradually increased by a healthcare professional depending on response and tolerance.

Mounjaro (tirzepatide) acts on two hormone pathways (GLP-1 and GIP), while Wegovy and Ozempic act on GLP-1 only. Individual response varies, and treatment suitability depends on clinical assessment.